- Home
- ATHR vs RCEL Comparison
ATHR vs RCEL Comparison
Compare ATHR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHR
- RCEL
- Stock Information
- Founded
- ATHR 2003
- RCEL N/A
- Country
- ATHR United States
- RCEL United States
- Employees
- ATHR N/A
- RCEL N/A
- Industry
- ATHR
- RCEL Medical/Dental Instruments
- Sector
- ATHR
- RCEL Health Care
- Exchange
- ATHR NYSE
- RCEL Nasdaq
- Market Cap
- ATHR 159.0M
- RCEL 161.5M
- IPO Year
- ATHR 2025
- RCEL N/A
- Fundamental
- Price
- ATHR $12.40
- RCEL $5.42
- Analyst Decision
- ATHR
- RCEL Strong Buy
- Analyst Count
- ATHR 0
- RCEL 4
- Target Price
- ATHR N/A
- RCEL $16.50
- AVG Volume (30 Days)
- ATHR 36.7K
- RCEL 316.4K
- Earning Date
- ATHR 08-22-2025
- RCEL 08-07-2025
- Dividend Yield
- ATHR N/A
- RCEL N/A
- EPS Growth
- ATHR N/A
- RCEL N/A
- EPS
- ATHR N/A
- RCEL N/A
- Revenue
- ATHR $1,406,012.00
- RCEL $71,661,000.00
- Revenue This Year
- ATHR N/A
- RCEL $57.16
- Revenue Next Year
- ATHR N/A
- RCEL $36.69
- P/E Ratio
- ATHR N/A
- RCEL N/A
- Revenue Growth
- ATHR N/A
- RCEL 41.35
- 52 Week Low
- ATHR $4.63
- RCEL $4.71
- 52 Week High
- ATHR $19.69
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- ATHR N/A
- RCEL 43.61
- Support Level
- ATHR N/A
- RCEL $5.11
- Resistance Level
- ATHR N/A
- RCEL $5.55
- Average True Range (ATR)
- ATHR 0.00
- RCEL 0.31
- MACD
- ATHR 0.00
- RCEL 0.10
- Stochastic Oscillator
- ATHR 0.00
- RCEL 69.61
About ATHR AETHER HOLDINGS INC
Aether Holdings Inc is an emerging financial technology platform company that offers proprietary research analytics, data and tools for both institutional and retail equity traders through flagship platform, SentimenTrader.com. Its platform currently provides coverage of U.S. equity and option securities, evaluating the equities and options markets and conducting assessments through analysts and technology daily.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.